QuantX Biosciences Raises $85M Series B to Advance Oral STAT6 and IL-17 Inhibitors
核心洞察
QuantX Biosciences (搜索) closed an oversubscribed $85 million Series B financing co-led by LAV (搜索) and Sanofi Ventures (搜索) to advance its computational drug discovery platform.
The funding will support clinical development of the company's best-in-class STAT6 oral small molecule inhibitor and IL-17 (搜索) oral small molecule inhibitor for immunology and inflammation.
The company has advanced multiple first-in-class candidates into IND-enabling studies within three years since its 2022 founding, bringing total funding to $130 million.
QuantX Biosciences (搜索) announced the completion of an oversubscribed $85 million Series B financing round co-led by LAV (搜索) and Sanofi Ventures (搜索), with additional participation from Hongshan (搜索) and existing investors. The Princeton, New Jersey-based company will use the proceeds to advance its lead oral small molecule programs targeting immunology and inflammation, including a STAT6 inhibitor (搜索) and an IL-17 inhibitor (搜索).
The financing brings QuantX's total capital raised to $130 million since its founding in 2022, marking a significant milestone for the computationally driven drug discovery company. The round was previously incubated by OrbiMed (搜索) and Creacion Ventures (搜索).
Advancing First-in-Class Oral Therapeutics
QuantX has developed a computational drug discovery platform that merges physics-based and statistical modeling with high-performance computing to rapidly design and optimize oral small molecule therapeutics. The company's approach is intended to reduce iteration cycles in early drug discovery while targeting clinically validated targets.
"This fundraising is a watershed moment for QuantX as we continue to refine our strong discovery engine, add to our robust pipeline, and advance multiple programs towards human studies," said Wei Li, Ph.D., Interim Chief Executive Officer of QuantX and a Founding Partner of Creacion Ventures (搜索). Li noted that the company has assembled a world-class team that has been successful in discovering multiple, new, first-in-class small molecule candidates for diseases with large patient populations and has advanced these to IND-enabling studies within three years.
The company's lead programs include a best-in-class STAT6 oral small molecule inhibitor and an IL-17 (搜索) oral small molecule inhibitor, both targeting immunology and inflammation indications. These programs represent the company's focus on building a pipeline of differentiated therapies for immune-mediated and inflammatory diseases (搜索).
Strategic Investment and Platform Validation
Sanofi Ventures (搜索)' participation as a co-lead investor signals continued interest by large pharmaceutical companies in externally developed computational discovery platforms, particularly those advancing oral therapies for immunology. The investment aligns with broader industry trends toward accessing early innovation through venture investing rather than in-licensing at later, higher-risk stages.
David Wang, MD, Ph.D., Partner and Senior Managing Director of OrbiMed (搜索), highlighted the company's unique value proposition. "The combination of QuantX's ability to deliver best-in-class assets and the speed by which they're able to advance these programs makes for a unique value proposition across a variety of therapeutic indications," Wang said. "We look forward to continuing our support of QuantX as they endeavor to transform the standards of care across a range of diseases."
Company Foundation and Leadership
QuantX Biosciences (搜索) was co-founded by veteran drug hunters Wayne Tang, Ph.D. and Yax Sun, Ph.D. in 2022. Since its inception, the company has focused on developing a world-class computational drug discovery platform that integrates physics-based modeling, statistical methods, and computational chemistry to rapidly design and optimize drug candidates against clinically validated targets.
The company's computational approach represents a differentiated strategy in the competitive drug discovery landscape, with the goal of improving development efficiency and success rates in bringing oral small molecule therapeutics to market for immune-mediated and inflammatory diseases (搜索).